356 related articles for article (PubMed ID: 22913770)
41. Joint WFH-ISTH session: issues in clinical trial design.
Peyvandi F; Farrugia A; Iorio A; Key NS; Srivastava A
Haemophilia; 2014 May; 20 Suppl 4():137-44. PubMed ID: 24762289
[TBL] [Abstract][Full Text] [Related]
42. Prophylactic infusion regimens in the management of hemophilia.
Ljung RC
Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
[TBL] [Abstract][Full Text] [Related]
43. Progress in the clinical management of haemophilia.
Bloom AL
Thromb Haemost; 1991 Jul; 66(1):166-77. PubMed ID: 1926047
[No Abstract] [Full Text] [Related]
44. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
Ljung RCR
Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
[TBL] [Abstract][Full Text] [Related]
45. Clinical trial design in haemophilia.
Dimichele DM; Blanchette V; Berntorp E
Haemophilia; 2012 Jul; 18 Suppl 4():18-23. PubMed ID: 22726077
[TBL] [Abstract][Full Text] [Related]
46. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
[TBL] [Abstract][Full Text] [Related]
48. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
49. Stretching time.
Savage N
Sci Am; 2015 Jan; 312(1):S8-10. PubMed ID: 25597117
[No Abstract] [Full Text] [Related]
50. Sodium content in products used to treat haemophilia.
Altisent C; Martorell M; de la Sierra A
Haemophilia; 2016 Jul; 22(4):e324-7. PubMed ID: 27228069
[No Abstract] [Full Text] [Related]
51. Safety of recombinant coagulation factors in treating hemophilia.
Morfini M; Rapisarda CAP
Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic properties and safety of recombinant factor VIII and factor IX.
Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
[TBL] [Abstract][Full Text] [Related]
53. Recent advances in developing specific therapies for haemophilia.
Ling G; Nathwani AC; Tuddenham EGD
Br J Haematol; 2018 Apr; 181(2):161-172. PubMed ID: 29359795
[TBL] [Abstract][Full Text] [Related]
54. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
[TBL] [Abstract][Full Text] [Related]
55. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
Mancuso ME; Mahlangu JN; Pipe SW
Lancet; 2021 Feb; 397(10274):630-640. PubMed ID: 33460559
[TBL] [Abstract][Full Text] [Related]
56. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
Shapiro AD; Korth-Bradley J; Poon MC
Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
[TBL] [Abstract][Full Text] [Related]
57. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
59. New high-technology products for the treatment of haemophilia.
Pipe SW; Saint-Remy JM; Walsh CE
Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
Morfini M; Farrugia A
Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
